Zepbound & Mounjaro: Eli Lilly’s "overnight" successes
At JPM2024, Eli Lilly’s CEO presented this graphic
to emphasize the point that it took decades of work
to get to the 2022 FDA approval of Mounjaro for Type 2 diabetes
and the November 2023 FDA approval of Zepbound for obesity
Tirzepatide, is the active ingredient in Zepbound and Mounjaro
Subscribe to get access to all the exciting upcoming obesity readouts. 👇
🔗 https://www.bpiq.com/pricing
Article History:
2/1/24 AV
This article is not investment or legal advice.
#LLY
7 Views